Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 | P09237 | 14/20 | 0.52 |
| ▸ | MMP1 | P03956 | 12/20 | 0.52 |
| ▸ | MMP3 | P08254 | 12/20 | 0.52 |
| ▸ | MMP13 | P45452 | 10/20 | 0.52 |
| ▸ | MMP9 | P14780 | 9/20 | 0.52 |
| ▸ | MMP2 | P08253 | 9/20 | 0.48 |
| ▸ | MMP8 | P22894 | 3/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | MMP16 | P51512 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639399 | 0.91 | MMP3 (0.51) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5639216 | 0.90 | MMP7 (0.65) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5638875 | 0.87 | MMP2 (0.45) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5636815 | 0.85 | MMP1 (0.50) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5636244 | 0.84 | KMT2A (0.51) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5637256 | 0.84 | MMP3 (0.53) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5639338 | 0.84 | MMP1 (0.56) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5636808 | 0.84 | MMP2 (0.48) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5636768 | 0.84 | MMP1 (0.49) | MMP7MMP1MMP3MMP13MMP9 | |
| SCHEMBL5639168 | 0.84 | MMP1 (0.61) | MMP7MMP1MMP3MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223751-B2 | Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same | KOLON IND. INC. (KR) | 2007-05-29 | — | — | US | disclosed |
| US-20040138206-A1 | Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same | KOLON LIFE SCIENCE, INC. (KR) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138206-A1 | Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same | MMP1, MMP7, STS | MMP7 2/4885MMP1 1/4885MMP3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.